Modelling Cost Effectiveness of Behaviour Modification Programmes and Effects on Medication Case Study of Education Programmes in Diabetes Professor Alan.

Slides:



Advertisements
Similar presentations
Ethnic differences in risks and explanations for the cardiometabolic syndrome in the UK Nish Chaturvedi Professor of Clinical Epidemiology Imperial College.
Advertisements

10 Points to Remember for the Management of Overweight and Obesity in Adults Management of Overweight and Obesity in Adults Summary Prepared by Elizabeth.
Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
Accounting for Psychological Determinants of Treatment Response in Health Economic Simulation Models of Behavioural Interventions A Case Study in Type.
Modelling Partially & Completely Missing Preference-Based Outcome Measures (PBOMs) Keith Abrams Department of Health Sciences, University of Leicester,
Challenges When Conducting Economic Evaluation Alongside Clinical Trials: Experience Of Economic Appraisal In Cardiovascular Disease Andrew Briggs University.
The Cost-Effectiveness of Providing DAFNE to Subgroups of Predicted Responders J Kruger 1, A Brennan 1, P Thokala 1, S Heller 2 on behalf of the DAFNE.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2009.
Methods to Analyse The Economic Benefits of a Pharmacogenetic (PGt) Test to Predict Response to Biologic Therapy in Rheumatoid Arthritis, and to Prioritise.
UKPDS Paper 81 Slides © University of Oxford Diabetes Trials Unit UKPDS slides are copyright and remain the property of the University of Oxford Diabetes.
ESH 2004 Paris1 Blood Pressure Control by Home Monitoring A Meta-Analysis of Randomised Trials FP Cappuccio, SM Kerry, L Forbes, A Donald Published in:
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
The concept of Diabetes & CV risk: A lifetime risk challenge
BINGE EATING AND OBESITY In this power point we will review what binge eating and obesity is how it can harm our health what treatments there are for binge.
Structured diabetes education has made little difference to patient outcomes Dr David Cavan Bournemouth Diabetes and Endocrine Centre
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
Evidence into Practice: Diabetes Public Health England May 2014 Dr Junaid Bajwa.
Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.
Self Management Support Dr. Patrick Doorley, HSE 25/10/2012.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Rapid E clinical guidance in the management of Type 2 diabetes New Zealand Guidelines Group.
The cost-effectiveness of providing a DAFNE follow- up intervention to predicted non-responders J Kruger 1, A Brennan 1, P Thokala 1, S Heller 2 on behalf.
SUPPORTING PRIMARY CARE TO ACHIEVE TARGETS. What targets? 1.9 care processes 2.3 health targets (HbA1c, blood pressure, cholesterol) AND IMPORTANTLY Quality.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年9月 25 日 8:20-8:50 B 棟8階 カンファレンス室.
Quality improvement in non glycaemic targets in diabetic patients at Central Australian Aboriginal Congress John Boffa Public Health Medical Officer.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
Take Five to Understand! 1. Eat Healthier Eating fewer calories and cutting down on saturated fat and carbohydrates can help lower weight, blood glucose.
Cumulative incidence of Diabetes after 50 years based on average BMI aged years Arch Intern Med 1999;159:
FDA Endocrinologic and Metabolic Drugs Advisory Committee 1st June 2008 Rury Holman Clinical outcomes with anti-diabetic drugs: What we already know.
Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY.
Proteinuria as a surrogate outcome in CKD UKPDS Rudy Bilous Middlesbrough, UK.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Exercise, Health & Lifestyle Unit 7 Reasons & Benefits of Taking Part In Physical Activity.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Pharmacist-Physician Collaborative Medication Therapy Management Services (MTMS) PI: Jan Hirsch, RPh, PhD Carol M. Mangione, MD, MSPH Barbara A. Levey.
END Obesity Dr Gul Bano © S Nussey. What is obesity?
2nd Concertation Meeting Brussels, September 8, 2011 Reinhard Prior, Scientific Coordinator, HIM Evidence in telemedicine: a literature review.
UKHDS (UKPDS): UK Hypertension in Diabetes Study Purpose To determine whether tight control of blood pressure (aiming for BP
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
1 Centre for Sport and Exercise Science, Sheffield Hallam University, U. K. 2 York Trials Unit, Department of Health Sciences, University of York, U. K.
STEPWISE: STructured lifestyle Education for People WIth SchizophrEnia Chris Dickens, Professor of Psychological Medicine University of Exeter Medical.
Diabetes Health intelligence Jon Walker Advanced public health analyst Surrey County Council
Diabetes Health intelligence Jon Walker Advanced public health analyst Surrey County Council
Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%)
Risk Factor Modification in CCR. How does CR work?
Ross T. Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC Yazid NJ Al Hamarneh, BPharm, PhD Charlotte Jones, MD, PhD, FRCP(C) Brenda Hemmelgarn, MD, PhD, FRCP(C)
If we followed NICE guidelines and treated people with diabetes earlier, patients and the NHS would benefit from a reduction in complications, mortality.
LifeCIT Development and pilot evaluation of a web-supported programme of Constraint Induced Therapy following stroke (LifeCIT) Meagher C 1, Conlon A 2,
Journal Club Julie Shah, MD Milton S Hershey Medical Center Penn State University.
Improving risk factor management for patients with poorly controlled type 2 diabetes: a systematic review of non-pharmaceutical interventions in primary.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.
Effect of a Community-Based Self-help Management Program for Patients with Diabetes Mellitus Effect of a Community-Based Self-help Management Program for.
Changes in the concentration of serum C-peptide in type 2 diabetes during long-term continuous subcutaneous insulin infusion therapy Department of Internal.
Powered by Infomedica Infomedica Conference Coverage* of 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13,
‘PhysioDirect’ for patients with MSK problems ECONOMIC MODEL OVERVIEW.
Dr John Cox Diabetes in Primary Care Conference Cork
Diabetes Health Status Report
Type 2 diabetes.
Growing Diabetes Pandemic Worldwide
Evaluating the cost-effectiveness of interventions with an impact on ageing P. Breeze, P. Thokala, L. Lafortune, C. Brayne, A. Brennan 07/12/2018.
Section overview: Cardiometabolic risk reduction
Masterclass on lifestyle change How to help patients lose weight?
Hertfordshire Community Diabetes Service Diabetes Dietitians
Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.
CONSORT flow diagram for the randomised controlled trial of the iCBT-MDD programme for people with diabetes. iCBT-MDD, internet-based cognitive behaviour.
Structured diabetes self-management education and the NDSS
Risk of cardiovascular disease mortality by cardiorespiratory fitness and body mass index categories, 2316 men with type 2 diabetes at baseline, 179 deaths.
HR for mortality in ischemic heart disease.
Nutrition Interventions to Improve Quality of Care
Presentation transcript:

Modelling Cost Effectiveness of Behaviour Modification Programmes and Effects on Medication Case Study of Education Programmes in Diabetes Professor Alan Brennan & Mike Gillett. Health Economics and Decision Science, ScHARR, UK. (1)To model long-term clinical and cost-effectiveness of the Diabetes Education and Self-Management for Ongoing and Newly Diagnosed (DESMOND) for people with newly diagnosed Type 2 diabetes, versus usual care in the UK. (2)To consider issues arising in modelling education / behaviour modification programmes and how modelling can support the development of clinical research. Objectives The modelling undertakes a long-term cost-utility analysis with evidence from a 12- month multicentre cluster RCT using the Sheffield Type 2 Diabetes Model. Short and long-term outcomes include Hba1c, lipids and systolic blood pressure, patients' weight and smoking status. The model examines long-term use of therapies including oral hypoglycemic agents. Risk / disease progression models based on UKPDS and other evidence 2, estimate incidence of complications, mortality, costs 3 and health-related quality of life 4,5,6. Medication Use, NHS Resources in trial, Unit Costs and Overall Cost Difference Methodology 1.Results suggest that DESMOND is cost effective compared to usual care. 2.Further modelling should include: whether maintenance of effect via longer-term top-up education is effective subgroup analysis of those who respond / do not respond direct modelling of exercise benefits adaptation to Type 1 diabetes education programmes such as Dose Adjustment for Normal Eating (DAFNE) Conclusions Differences in Cardiovascular Risk Factors in the DESMOND Trial Biomedical Markers and Smoking Rates at Month 12 Conditional likelihood of smoking at month 12 given baseline status Conceptual Diagram for Sheffield Type 2 Diabetes Model 1.Davies MJ, Heller S, Skinner TC, Campbell MJ, Carey ME, Cradock S, et al; Diabetes Education and Self Management for Ongoing and Newly Diagnosed Collaborative. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ 2008;336: Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47: Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003;20: Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22: Coffey JT, Brandle M, Zhou H, Marriott D, Burke R, Tabaei BP, et al. Valuing health-related quality of life in diabetes. Diabetes Care. 2002;25: Warren E, Brennan A, Akehurst R. Cost-effectiveness of sibutramine in the treatment of obesity. Med Decis Making Jan- Feb;24(1):9-19 Results